AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 142 min read$PDSB

Patrick Soon-Shiong joins PDS Biotechnology (PDSB) board in up to $22M PIPE deal

PDS Biotechnology (PDSB) raised $11.3M in a PIPE deal led by Dr. Patrick Soon-Shiong, who joined the board. The funds will repay debt and advance clinical programs, including PDS0301 for colorectal cancer. Soon-Shiong's NantWorks gained a licensing option for PDS0101.

Original reporting
stocktitan.net
Published Sep 14, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PDSB
Bullish
medium confidence
Mentioned
$PDSB
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PDSBBullishMed
01

Why it matters

The $22M PIPE provides needed capital for advancing PDS0301 into late‑stage trials and adds Dr. Soon‑Shiong's expertise, potentially improving the company's valuation.

02

Market read

Primary corporate financing event for a micro‑cap biotech; may attract short‑term trading interest.

03

What to watch

Execution risk of the Phase 3 trial and reliance on a single high‑profile director.

Relevance 6/10Novelty 7/10Timing: Sep 14, 2026 (today)

Background

PDS Biotechnology (Nasdaq: PDSB) is a clinical‑stage company developing IL‑12 immunocytokine therapies for cancer.

Company-level read

Ticker impact

$PDSBBullishMedium confidence
Context

PDS Biotechnology announced an up to $22.3M PIPE financing and appointed Dr. Patrick Soon-Shiong to its board, providing fresh capital and a high-profile director.

Expected impact

Potential modest upside as investors price in new funding and board credibility.

Evidence & confidence

PIPE financing is a primary corporate action; the amount is material for a micro‑cap biotech and the board addition adds credibility.

Market effects

Sector

May boost sentiment for the oncology immunotherapy sector as a peer secures new funding.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The PIPE dilution could pressure existing shareholders; the raise may signal cash burn concerns.

Key entities

  • Company
    PDS Biotechnology

    Clinical‑stage biotech focused on targeted immunotherapies.

  • Individual
    Patrick Soon‑Shiong

    Renowned biotech entrepreneur and new board member of PDSB.

  • Investor
    Nant Capital

    Lead investor in the PIPE financing.

Read at source← All news

Related articles

SEP 22
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min
SEP 8
$PDSBHighAI 8/10

80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment

PDS Biotech (PDSB) secured a PIPE financing of up to $22.55M led by Nant Capital, with an initial closing of $11.55M expected by September 11, 2026. The funds will support late-stage development of PDS0301, following Phase 2 trial data showing 80% 24-month survival in 22 metastatic colorectal cancer patients. Nant Capital may designate two board members, including Dr. Patrick Soon-Shiong, while owning at least 15% of the common stock.

stocktitan.net2 min
AUG 19
$PDSBLow

PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs

PDS Biotechnology (PDSB) announced CFO Lars Boesgaard's resignation effective September 12, 2026. CEO Frank Bedu-Addo will serve as interim Principal Financial Officer, while Janetta Trochimiuk becomes interim Principal Accounting Officer with a $279,519.57 annual salary. Boesgaard's departure is not due to disagreements. Trochimiuk remains eligible for future equity awards.

stocktitan.net1 min